title: Prognostic factors for survival in cervical cancer patients with bone metastasis.
abstract: OBJECTIVE
  To investigate the prognostic factors for survival in uterine cervical cancer patients who developed bone metastasis.
  
  
  METHODS
  Cervical cancer patients with bone metastasis who were treated at the present institute from April 1996 to September 2010 were identified from the authors' institutional tumor registries. Primary disease, follow-up, and recurrence data were collected and retrospectively reviewed. Univariate and multivariate analyses of prognostic factors for survival were performed.
  
  
  RESULTS
  A total of 37 patients that developed cervical cancer bone metastasis were included in the authors' database. The median survival time after recurrence was 12 months. Univariate analysis revealed that patients with a disease-free interval (DFI) of ten months or less achieved significantly shorter survival after bone metastasis detection than those with a DFI of 11 months or more (median: 8.5 months versus 17 months, p < 0.0001). Multivariate analysis also showed that DFI of ten months or less was a significant predictor of short survival (p = 0.0018).
  
  
  CONCLUSIONS
  The DFI was found to be independent prognostic factors for survival in cervical cancer patients who developed bone metastasis.
authors.forename: T
authors.initials: T
authors.lastname: Kanayama
authors.forename: S
authors.initials: S
authors.lastname: Mabuchi
authors.forename: K
authors.initials: K
authors.lastname: Shimura
authors.forename: T
authors.initials: T
authors.lastname: Hisamatsu
authors.forename: F
authors.initials: F
authors.lastname: Isohashi
authors.forename: T
authors.initials: T
authors.lastname: Hamasaki
authors.forename: T
authors.initials: T
authors.lastname: Kimura
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D018196:Carcinoma, Adenosquamous / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010166:Palliative Care; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents